For the Inventor, By the Inventor

Enter assignee name

Cellectis S.a.

USPTO Granted Patents = 20

% Expired Patents = 20.0

EPO Patents = 10

Trademarks = 1

Forward Citations = 53

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Philippe Duchateau (7 out of 55 patents)

Jean-Charles Epinat (5 out of 12 patents)

Alan D King (4 out of 11 patents)

4. Sylvain Arnould (4 out of 5 patents)

5. Patrick Chames (4 out of 5 patents)

6. Emmanuel Lacroix (4 out of 6 patents)

7. Richard E Walters (3 out of 16 patents)

8. Phillippe Duchateau (3 out of 3 patents)

9. Frederic Paques (3 out of 6 patents)

10. Marc-Andre D'Aoust (2 out of 35 patents)

11. Daniel F Voytas (2 out of 29 patents)

12. Claudia Bertonati (2 out of 7 patents)

13. Alexandre Juillerat (2 out of 19 patents)

14. Thomas Stoddard (2 out of 4 patents)

15. Luc Mathis (2 out of 6 patents)

20 patents: Sort by Forward Citations

1. 12618048 - DUAL CAR-T CELLS (2026-05-05),

2. 12534744 - METHODS TO GENETICALLY MODIFY CELLS FOR DELIVERY OF THERAPEUTIC PROTEINS (2026-01-27),

3. 12133867 - Universal anti-CD22 chimeric antigen receptor engineered immune cells (2024-11-05),

4. 11944643 - Universal anti-CD22 chimeric antigen receptor engineered immune cells (2024-04-02),

5. 11778993 - Repeat variable diresidues for targeting nucleotides (2023-10-10),

6. 11690873 - Universal chimeric antigen receptor T cells specific for CD22 (2023-07-04),

7. 11578318 - Large volume ex vivo electroporation method (2023-02-14),

8. 11576317 - Mutantplant or cell with reduced XylT and FucT (2023-02-14),

9. 11555198 - Method for making nicotiana plants with mutations in XylT and FucT alleles using rare-cutting endonucleases (2023-01-17),

10. 10494626 - Dynamic mixing and electroporation chamber and system (2019-12-03),

11. 9982251 - Large volume ex vivo electroporation method (2018-05-29),

12. 9315788 - Method for the generation of compact TALE-nucleases and uses thereof (2016-04-19),

13. 9044492 - Method for modulating the efficiency of double-strand break-induced mutagenesis (2015-06-02),

14. 8927247 - [object Object] (2015-01-06),

15. 8697395 - Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof (2014-04-15),

Company Overview

Cellectis S.A. is a biotechnology company based in France, specializing in gene editing and cell therapy. The organization focuses on developing innovative therapies for cancer treatment, leveraging its proprietary technologies to create engineered T cells. Cellectis aims to advance the field of immunotherapy through its research in genome editing, particularly utilizing the CRISPR technology platform. The company is committed to transforming the landscape of cancer treatment by harnessing the power of the immune system to target and eliminate cancer cells.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

20 Patents

#36 in

#1,013 in France

#31,295 in the World

Cellectis S.a.

Forward Citations = 53

45 inventors:

Philippe Duchateau (7 out of 55 patents)

Jean-Charles Epinat (5 out of 12 patents)

Alan D King (4 out of 11 patents)

4. Sylvain Arnould (4 out of 5 patents)

5. Patrick Chames (4 out of 5 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cellectis S.a.. Retrieved from https://idiyas.com/company/cellectis-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…